1Kobashigawa JA, Katznelson S, Laks H, et al Effect of pravastatin on outcomes after cardiac transplantation[J]. N Engl J Meal,1995,333:621-627.
2Youssef S, Stuve O, Patarroyo JC, et al. The HMGCoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous systern autoimmune disease [J]. Nature, 2002, 420.- 78- 84.
3Aktas O, Waiczies S, Smorodchenko A, etal. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Thl cells through atorvastatin [J]. J Exp Med, 2003,197:725-733.
4Nath N, Giri S, Prasad R, et al. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy [J]. J Immunol, 2004,172-1273 1286.
5Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators: comparison with interferon-beta lb in MS[J]. Neurology, 2002,59.- 990-997.
6Peng X, Jin J, Girl S, et al. Immunomodulatory effects of 3-hydroxy 3 methylglutaryl coenzyme A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis [ J ]. J Neuroimmunol, 2006,178: 130-139.
7Dunn SE, Youssef S, Goldstein MJ, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity byatorvastatin[J]. J Exp Med, 2006,203:401 -412.
8Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis[J]. Lancet, 2004,363 : 1607-1608.
9Zeinstra E, Wilczak N, Chesik D, et al. Simvastatin inhibits interferon gammanduced MHC class Ⅱ upregulation in cultured astrocytes[J]. J Neuroinflamma tion,2006,3:16.
10Liao JK. Isoprenoids as mediators of the biological effects of statins[J]. J Clin Invest, 2002,110:285 -288.
